For instance, a phase I study on combination treatment of taxanes with inhibitors targeting Mps1 demonstrated an anti-tumor activity in 32% of patients with solid tumors, establishing a precedent for further clinical trials.90 This evidence concerns the gene TTK and neoplasm.